Sex-dependent VEGF expression underlies variations in human pluripotent stem cell to endothelial progenitor differentiation

Lauren N. Randolph1,2, Xiaoping Bao4, Michael Oddo1 & Xiaojun Lance Lian1,2,3*

Human pluripotent stem cells (hPSCs) offer tremendous promise in tissue engineering and cell-based therapies because of their unique combination of two properties: pluripotency and a high proliferative capacity. To realize this potential, development of efficient hPSC differentiation protocols is required. In this work, sex-based differences are identified in a GSK3 inhibitor based endothelial progenitor differentiation protocol. While male hPSCs efficiently differentiate into CD34+ CD31+ endothelial progenitors upon GSK3 inhibition, female hPSCs showed limited differentiation capacity using this protocol. Using VE-cadherin-GFP knockin reporter cells, female cells showed significantly increased differentiation efficiency when treated with VEGF during the second stage of endothelial progenitor differentiation. Interestingly, male cells showed no significant change in differentiation efficiency with VEGF treatment, but did show augmented early activation of VE-cadherin expression. A sex-based difference in endogenous expression of VEGF was identified that is likely the underlying cause of discrepancies in sex-dependent differentiation efficiency. These findings highlight the importance of sex differences in progenitor biology and the development of new stem cell differentiation protocols.

In the regenerative medicine field, topics such as personalized medicine, immunoengineering, and stem cell therapies are frequently discussed; however, cell sex variations are rarely considered despite prevalent evidence of sex differences in many different diseases, such as cardiovascular disease, autoimmune disease, Alzheimer disease, and diabetes1–6. Many of these conditions involve malfunction or attack of terminally differentiated senescent cells making them excellent candidates for the development of stem cell-based therapies. Efforts in the stem cell biology field to derive these somatic cell types have progressed substantially, and in some cases, have produced efficient differentiation strategies7–9.

Endothelial progenitors and vascular endothelial cells, arising from the mesodermal germ layer, are of great interest in a variety of regenerative medicine, tissue engineering, and other research applications. One of the predominant challenges in the field of tissue engineering is vascularization in solid tissues. This requires efficient generation of endothelial progenitor cells that yield cells of the vasculature and would provide relevant materials for in vitro models of diseases in which endothelial cells play an important role, such as cardiovascular disease10–14. Additionally, endothelial progenitors with definitive hematopoietic potential are of great importance in developing directed differentiation strategies towards hematopoietic stem cells and blood cell components for therapeutic applications, such as hematopoietic stem cell transplant and T-cell based cancer therapies15–17. Directed differentiation strategies applied to human pluripotent stem cells (hPSCs) provide an infinite cell source as hPSCs can be propagated indefinitely while still retaining the capacity to differentiate into all manner of somatic cell types18–21. Furthermore, genetic disease context can be introduced using induced pluripotent stem cells (iPSCs) derived from relevant patient populations20,21. hPSCs also provide a platform for developing model systems, using genome editing technology such as CRISPR-Cas9, to elucidate the cellular signals involved in differentiation to a somatic cell type22–26.

1Department of Biomedical Engineering, Pennsylvania State University, University Park, PA, 16802, USA. 2Huck Institutes of the Life Sciences, Pennsylvania State University, University Park, PA, 16802, USA. 3Department of Biology, Pennsylvania State University, University Park, PA, 16802, USA. 4Davidson School of Chemical Engineering, Purdue University, West Lafayette, IN, 47907, USA. *email: Lian@psu.edu
A variety of directed differentiation strategies for deriving endothelial cells from hPSCs have been established, including chemically defined small molecule based protocols. This protocol efficiently produces endothelial progenitor cells from hPSCs via GSK3 inhibition to activate the Wnt signaling pathway. Using this strategy, it is possible to efficiently generate CD34<sup>+</sup>CD31<sup>+</sup> VE-cadherin<sup>+</sup> endothelial progenitor cells from male hPSCs; however this differentiation strategy proved inefficient for the differentiation of female hPSCs. While it is common practice to perform experiments on a variety of cell lines to validate new findings or protocols, it is less common to specifically compare differences that might exist as a function of a cell's sex, and the sex of a cell line is often not reported. In fact, many protocols discussing directed differentiation to a somatic cell type of interest use all male or all female cell lines. In order to generate clinically useful cells with universal applicability, a directed differentiation method that works efficiently for both male and female cells is crucial. No studies have been done with hPSCs to show that a differentiation strategy might result in different outcomes or differentiation efficiencies with relation to cell sex. Some research has shown sex differences in differentiated somatic cell types. For example, variance in skeletal muscle regeneration capacity and the oxidative stress response of male and female muscle-derived stem cells have been identified. Sex hormones and receptors have also been shown to affect only female hematopoietic stem cell self-renewal. Distinctions in proliferation of smooth muscle progenitor cells derived from hPSCs have also been shown as a function of cell sex in addition to disparity in extracellular matrix protein expression in these cells; however, no difference in differentiation efficiency was observed. Differences in autosomal gene expression between male and female hPSCs have been reported, suggesting that male and female cells could respond differently to the same differentiation stimuli. The identification of sex-based variations in response to differentiation cues would provide critical insight into the function of sex in endothelial progenitor development. This could have broad implications in progenitor cell biology as well as the development and implementation of therapeutic products using the vascular and hematopoietic cells that are derived from this progenitor stage.

Many methods, currently used to generate endothelial progenitors for further differentiation to hemogenic or endothelial lineages, rely on the use of VEGF among other growth factors. Variations in skeletal muscle regeneration capacity and the oxidative stress response of male and female muscle-derived stem cells have been identified. Sex hormones and receptors have also been shown to affect only female hematopoietic stem cell self-renewal. Distinctions in proliferation of smooth muscle progenitor cells derived from hPSCs have also been shown as a function of cell sex in addition to disparity in extracellular matrix protein expression in these cells; however, no difference in differentiation efficiency was observed. Differences in autosomal gene expression between male and female hPSCs have been reported, suggesting that male and female cells could respond differently to the same differentiation stimuli. The identification of sex-based variations in response to differentiation cues would provide critical insight into the function of sex in endothelial progenitor development. This could have broad implications in progenitor cell biology as well as the development and implementation of therapeutic products using the vascular and hematopoietic cells that are derived from this progenitor stage.

**Results**

**Generation and validation of VE-cadherin knockin hPSC lines.** Several VE-cadherin (VEC)-GFP knockin (KI) reporter hPSC clones were generated to allow easy and antibody free isolation, quantification, and tracking of cells successfully differentiated to endothelial progenitors (Fig. 1A). A donor plasmid was designed with the desired insert, eGFP, preceded by a 2A sequence and followed by a floxed PGK-Puro<sup>+</sup> cassette, and the S′ and 3′ homology arms based on the sequence immediately before and after the VEC stop codon respectively (Fig. 1B). After electroporation, single cell derived colonies were isolated and tested to identify successful heterozygous KI clones.

To validate the function of the VEC-GFP KI cells, male H13 VEC-GFP KI cells and wild type H13 cells were differentiated to endothelial progenitor cells without VEGF in 5 days. Flow cytometry analysis was then used to evaluate the expression of GFP and obtained ~22% of the KI cells expressing VEC-GFP while no GFP positive population was observed with the wild type cells as expected (Fig. 1C). This efficiency is consistent with previous reports.

**VEGF supplementation enables generation of endothelial progenitor cells from female hPSCs.** To determine whether supplementation with VEGF during endothelial progenitor differentiation would increase differentiation efficiency for female hPSCs, H9 (female) and H13 (male) VEC-GFP KI cells were differentiated with or without 100 ng/mL VEGF<sub>165</sub> added into the media from day 2 to day 5. Whereas GFP positive cells were detected with or without VEGF<sub>165</sub> treatment for male H13 hPSCs, GFP positive cells were only detectable with VEGF<sub>165</sub> treatment for H9 cells (Fig. 2A). To quantify changes in efficiency of the differentiation, the percentage of the day 5 cells that were expressing GFP was analyzed using flow cytometry from a minimum of 6 independent differentiations. The addition of VEGF<sub>165</sub> allowed the emergence of a GFP<sup>+</sup> endothelial progenitor population in H9 cells totaling approximately 36% of the cells as compared to <0.1% without VEGF<sub>165</sub> (Fig. 2A,B). The differentiation efficiency obtained by adding VEGF<sub>165</sub> with the female cells is comparable to the originally and currently reported efficiencies obtained with male cells, if not higher. Furthermore, statistical analysis via two-tailed student's t-test showed there was a statistically significant difference in the percentage of the GFP<sup>+</sup> population between the H9 cells differentiated with and without VEGF<sub>165</sub> (p < 0.001). For wild type H9 cell differentiation with VEGF<sub>165</sub> treatment, similar differentiation efficiency was achieved, which highlights that electroporation and KI procedures do not affect differentiation (Supplementary Fig. S1). For male H13 cells, there was no statistically significant difference between the two conditions (with or without VEGF<sub>165</sub> (Fig. 2A,B). Statistical analysis with a two-way ANOVA and a Bonferroni post hoc test showed that the sex of the cells and interaction between the cell sex and VEGF<sub>165</sub> presence produced statistically significant effects on the differentiation efficiency (p < 0.001). All flow plots, including controls, are shown in Supplementary Fig. S2.

To evaluate the effects of VEGF<sub>165</sub> supplementation on the temporal kinetics of VEC expression, a western blot was performed using cell lysate collected from cells during each day of endothelial progenitor differentiation from day 0–5. β-actin protein content was used as a loading control (Supplementary Fig. S3). Without VEGF<sub>165</sub>, male H13 hPSCs showed strong VEC expression on day 5 as well as weaker expression on day 4 whereas female cells showed barely detectable VEC expression on day 5 (Fig. 2C). However, upon the addition of VEGF<sub>165</sub> strong
VEC expression is detected on both day 4 and 5 in female H9 cells and a notable increase in day 4 VEC expression is seen in male H13 cells (Fig. 2C).

Endogenous VEGF expression varies based on a cell’s sex. Based on the effects of VEGF supplementation on the kinetics of VEC expression and previous assumptions that endogenously secreted VEGF165 in male hPSCs was sufficient to promote endothelial progenitor differentiation, endogenous VEGF165 expression levels were quantified for comparison. RNA was collected from each day of the differentiation performed without VEGF supplementation, from hESC lines H1 (male), H9 (female), and iPSC lines 19-9-11 (male), IMR90C4 (female). Bright field images of H1 and H9 cell differentiation were taken daily during endothelial progenitor differentiation (Supplementary Fig. S4). qPCR analysis was performed to quantify the relative expression of VEGF165, SOX2 (a pluripotency marker), and CD34 (an endothelial progenitor marker). Both male and female cells showed decreasing expression of SOX2 over the course of the differentiation from D0 to D5, which was expected due to loss of pluripotency (Fig. 3A). The male cells also showed a spike in CD34 expression on D5 (Fig. 3A), indicating successful derivation of endothelial progenitor cells and aligning with previous reports showing CD34 expression over the course of this differentiation45. Interestingly, the female cells showed diminished activation of VEGF expression and no statistically significant increase over the day 0 expression level for both female hESCs and iPSCs (Fig. 3B). Additional comparison of the expression level of VEGF165 on day 5 between male and female cells showed that the male cells have significantly higher expression than the female cells at this point in the differentiation (p < 0.0001).

Discussion
In order to better understand the causes underlying sex-based differences in endothelial progenitor differentiation from hPSCs, VEC-GFP KI hPSCs were generated and used to show that supplementation with VEGF causes a significant increase in efficiency of endothelial progenitor differentiation in female cells increasing from less than 1% to 36%, but shows no significant change in differentiation efficiency with male cells. Furthermore, the addition of VEGF augmented the existing activation of VEC in male cells by increasing expression on Day 4.
and replicated this trend in female cells. In contrast, female cells without VEGF showed no activation on day 4 and minimal VEC expression on day 5 indicative of differences in cellular signaling activation related to VEGF. However, no premature emergence of VEC expression is observed with VEGF165 supplementation indicated that the addition of VEGF165 is augmenting signaling pathways already activated as opposed to deviating from the desired developmental program.

To elucidate the cause of this difference, endogenous VEGF165 expression was quantified. The data revealed a statistically significant difference in endogenous VEGF expression on day 5 male and female cells. This represents the first report of a sex difference in response to in vitro stem cell differentiation stimulus.

Efficiencies obtained for this differentiation (<50%) do not indicate that the most effective means of deriving endothelial progenitors has been identified; there may be additional signaling pathways that require activation or inhibition to better promote the endothelial progenitor cell fate. However, identification of intrinsic differences between male and female hPSCs that receive the same treatment and stimulation are of importance for both the design of research studies and downstream therapeutic development. Many groups performing stem cell

Figure 2. Effects of VEGF supplementation on endothelial progenitor differentiation in male and female cells (A) Representative flow cytometry analysis results showing VEC-GFP expression in H9 (female, left column) and H13 (male, right column) VEC-GFP KI cells after endothelial progenitor differentiation with (bottom row) or without (top row) VEGF (B) Quantification of flow cytometry analysis where each punctum represents an individual experiment (N = 7 for both conditions with H9 and N = 6 for both conditions with H13, ***p < 0.001). (C) Western blot showing the expression of VEC as the cells differentiate with or without VEGF for H9 and H13 cells. β-actin is a housekeeping control.
research use both male and female cells in their work. However, it is not always a standard that is met. Biased research using male or female cells can result in the development of therapeutics with inherent tailoring to one sex. Understanding differences between the sexes is also a key point of study in the developmental biology. Here, a select number of hPSC lines have been examined, and this may in turn limit the broader applicability of these results. Further in-depth study of this phenomenon in more hPSC lines, as it applies to both downstream differentiation from endothelial progenitors and other developmental lineages, and careful consideration of its effect on experimental design could lead to long sought solutions to elusive directed differentiation strategies.

In summary, the addition of VEGF to the previously established differentiation protocol overcomes identified efficiency differences in male and female hPSC differentiation to endothelial progenitor cells. While VEGF is often added in endothelial differentiation protocols, evidence is provided for a sex-based variation in its effect on differentiation efficiency. Taken together, the data point to intrinsic differences in VEGF signaling between male and female cells in response to the same endothelial progenitor differentiation method. This work augments the growing body of work highlighting the importance of evaluating the role of sex in stem cell differentiation, particularly when generating cells with immediate clinical application.

---

**Figure 3.** Analysis of endogenous VEGF expression in male and female cells during endothelial differentiation (A) qPCR results from two male cell lines: 6-9-9 (male iPSCs) and 19-9-11 (male iPSCs), and (B) two female cell lines: H9 (female hESCs) and IMR90C4 (female iPSCs), showing expression of VEGF, SOX2, and CD34 over the course of endothelial progenitor differentiation. Student’s T-test was performed to evaluate statistical significance between D0 and D5 expression for VEGF and is indicated on the plot. (ns: not significant, *p < 0.05, ****p < 0.0001).
Methods

Maintenance of hPSCs. Human pluripotent stem cells (Female: H9 hESCs, IMR90C4 iPSCs; Male: H13 and H1 hESCs, 19-9-11 iPSCs) were maintained on Matrigel (Corning)-coated plates in LaSR pluripotent stem cell medium according to previously published methods. LaSR pluripotent stem cell media does not contain any sex steroids. All cell culture experiments involving human pluripotent stem cell lines were approved by the Embryonic Stem Cell Oversight Committee at the Pennsylvania State University and carried out in accordance with the approved guidelines. All hPSC lines were obtained from WiCell. Informed consent was obtained from all subjects.

Construction of CDH5 donor plasmid and sgRNA. Donor plasmid construction and sgRNA cloning was performed as previously described. Briefly, DNA fragments located before and after the stop codon of CDH5 approximately 2 kb in length were PCR amplified from genomic DNA and cloned into OCT4-2A-eGFP-PKG-Puro. (This plasmid was a gift from Rudolf Jaenisch; Addgene #31938), replacing the OCT4 homology arms. pSpCas9(BB)-2A-Puro (PX459) V2.0 (This plasmid was a gift from Feng Zhang; Addgene #62988) was digested with BbsI and a one of two sgRNAs targeted up- and downstream of the CDH5 stop codon (sgRNA1: TCA GCC ACA ATC TTA AACC TTGGG and sgRNA2: TTT TTT GAG GCC GTG TTG GGT CCTTG) were inserted.

Electroporation. H13 and H9 hPSCs were treated with 10 μM ROCK inhibitor (Y27632) for 3 to 4 hours prior to electroporation. Cells were digested by Accutase at 37 °C for 10 min and 2.5–3 million singularized cells were electroporated with 3 μg gRNA1, 3 μg gRNA2, and 6 μg CDH5-2A-eGFP donor plasmids in 200 μl cold PBS using the Gene Pulser Xcell System (Bio-Rad) at 320V, 200 μF, and 1,000 Ω in a 0.4 cm cuvette. After electroporation, the cells were cultured in mTeSR1 and underwent drug selection using puromycin to remove any unmodified cells. The cells were then plated as single cells and allowed to form single cell-derived colonies. These cells were then picked and PCR genotyping was used to identify a successful heterozygous knock in clone. These cells were then treated with Cre recombinase to remove the puromycin resistance cassette, and single cell colony selection was performed again to isolate a heterozygous clone with successful excision of PGK-Puro.

Endothelial progenitor differentiation of hPSCs. Cells were differentiated to the endothelial progenitor state as previously described. Briefly, 50,000 cells/cm² were seeded onto a Matrigel-coated plate in LaSR pluripotent stem cell medium supplemented with 5 μg Y27632 (Selleckchem) on day -2. From day 0–1, the differentiation was initiated by changing media with LaSR basal medium supplemented with 6 μM CHIR99021 (Selleckchem). On day 2 the media was changed a final time with LaSR basal medium and some conditions were supplemented with 100 ng/mL VEGF165 (PeproTech). Cells were analyzed on day 5.

Flow cytometry analysis. Cells were dissociated into single cells with Accutase for 10 min at 37 °C and then added at a 1:2 v/v ratio to DPBS with 0.5% BSA. Data were collected on a Beckman Coulter FC500 flow cytometer or a BD Accuri C6 cytometer and analyzed using FlowJo. Gating was done based on the corresponding untreated cell control.

Western blotting. Cells were washed with DPBS and lysed with Mammalian Protein Extraction Reagent (Thermo Fisher) with 1X Halt’s Protease and Phosphatase (Thermo Fisher) by incubation for 3 minutes. Cell lysate was collected and stored at −80 °C until used. Samples were mixed with Laemmli sample buffer (BioRad) at a working concentration of 1X and incubated at 97 °C for 5 minutes. Samples were loaded into a pre-cast MP TGX stain free gel (BioRad) and run at 200V for 30 min in 1X Tris/Glycine/SDS buffer (BioRad). Protein was transferred to a PVDF membrane using a Trans-blot Turbo Transfer System (BioRad). The membrane was blocked for 30 minutes at room temperature in 1X TBST+ 5% Dry Milk. The membrane was incubated overnight at 4 °C with primary antibodies and for 1 hour at room temperature with secondary antibodies (Supplementary Table 1) in 1X TBST+ 5% Dry Milk. The membrane was washed between each antibody exposure with 1X TBST. Chemiluminescence was activated using Clarity Western ECL Substrate (BioRad) and the blot was imaged using a ChemiDoc Touch Imaging System and Image Lab software (BioRad).

Quantitative PCR (qPCR). RNA was extracted from the cells on each day of differentiation using a Direct-zol RNA Miniprep Plus Kit (Zymo Research R2071). A Maxima First Strand cDNA Synthesis kit (Thermo Fisher K1641) was used to generate cDNA. An Applied Biosystems QuantStudio3 was used for performing qPCR with Power SYBR Green PCR Master Mix (Applied Biosystems 4367659) and primers (Supplementary Table 2). Each sample was run in triplicate. Data was analyzed by normalizing target gene C values to GAPDH C values. Relative expression to GAPDH was set to zero in the event that no measurable gene expression was detected.

Statistics. Data obtained from multiple experiments or replicates are shown as the mean ± standard error of the mean. Where appropriate, Student’s t test or two-way ANOVA were utilized (alpha = 0.05) with a Bonferroni post hoc test. Data were considered significant when p < 0.05. Statistical tests were performed using custom MATLAB scripts.

Data availability The data sets obtained and used in this study are available upon request submitted to the corresponding author. The scripts used for data analysis in this study are available upon request submitted to the corresponding author.

Received: 13 May 2019; Accepted: 28 October 2019;
Published online: 13 November 2019
References

1. Ding, E. L., Song, Y., Malik, V. S. & Liu, S. Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes. *JAMA* **295** (2006).

2. Evans, M. et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. *Circulation* **101**, 2040–2046 (2000).

3. Fairweather, D., Frisanko-Kiss, S. & Rose, N. R. Sex differences in autoimmune disease from a pathological perspective. *Am. J. Pathol.* **173**, 600–609 (2008).

4. Mielke, M. M., Vemuri, P. & Rocca, W. A. Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences. *Clin. Epidemiol.* **6**, 37–48 (2014).

5. Kim, S. H. & Reaven, G. Sex Differences in Insulin Resistance and Cardiovascular Disease Risk. *J. Clin. Endocrinol. Metab.* **98**, E1716–E1721 (2013).

6. Intapad, S., Ojeda, N. B., Dasinger, J. H. & Alexander, B. T. Sex Differences in the Developmental Origins of Cardiovascular Disease. *Physiology* **29**, 122–132 (2014).

7. Lian, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc. Natl. Acad. Sci.* **109**, E1848–E1857 (2012).

8. Lian, X. et al. Chemically defined, albumin-free human cardiomyocyte generation. *Nat. Methods* **12**, 595–596 (2015).

9. Lian, X. et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. *Nat. Protoc.* **8**, 162–175 (2013).

10. MacAskill, M. G. et al. Robust revascularisation in multiple models of limb ischemia using a clinically translatable human stem cell-derived endothelial cell product. *Mol. Ther.* **26**, 1–16 (2018).

11. Belair, D. G. et al. Human Vascular Tissue Models Formed from Human Induced Pluripotent Stem Cell Derived Endothelial Cells. *Stem Cell Rev. Reports* **11**, 511–525 (2015).

12. Li, Z. et al. Differentiation, survival, and function of embryonic stem cell-derived endothelial cells for ischemic heart disease. *Circulation* **116**, 46–55 (2007).

13. Lee, S. et al. Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes. *Biomaterials* **63**, 138–167 (2015).

14. Wang, Z. Z. et al. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. *Nat. Biotechnol.* **25**, 317–8 (2007).

15. Galat, Y. et al. Cytokine-free directed differentiation of human pluripotent stem cells efficiently produces homogenous endothelium with lymphoid potential. *Stem Cell Res. Ther.* **8**, 67 (2017).

16. Sugimura, R. et al. Haematopoietic stem and progenitor cells from human pluripotent stem cells. *Nature* **545**, 432–438 (2017).

17. Shukla, S. K. et al. Progenitor T–cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1. *Nat. Methods* **14**, 531–538 (2017).

18. Takahashi, K. et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. *Cell* **131**, 861–872 (2007).

19. Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. *Science* **282**, 1145–7 (1998).

20. Millman, J. R. et al. Generation of stem cell-derived β-cells from patients with type 1 diabetes. *Nat. Commun.* **7**, 11463 (2016).

21. Fhöss, J. et al. Titin mutations in IPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. *Science* **349**, 982–987 (2015).

22. Inoke, M. et al. A Programmable Dual-RNA – Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science* (200), 337, 816–822 (2012).

23. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–23 (2013).

24. Mali, P. et al. RNA-guided human genome engineering via Cas9. *Science* **339**, 823–6 (2013).

25. Lian, X., Xu, J., Bao, X. & Randolph, L. N. Interrogating Canonical Wnt Signaling Pathway in Human Pluripotent Stem Cell Fate Decisions Using CRISPR-Cas9. *Cell. Mol. Bioeng.* **9**, 323–334 (2016).

26. Elliott, D. A. et al. NXX2–5(eGFP) hHESCs for isolation of human cardiac progenitors and cardiomyocytes. *Nat. Methods* **8**, 1037–40 (2011).

27. Lian, X. et al. Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling. *Stem Cell Reports* **3**, 804–816 (2014).

28. Bao, X. et al. Chemically-defined albumin-free differentiation of human pluripotent stem cells to endothelial progenitor cells. *Stem Cell Res.** **15**, 122–129 (2015).

29. Ikuno, T. et al. Efficient and robust differentiation of endothelial cells from human induced pluripotent stem cells via lineage control with VEGF and cyclic AMP. *PLoS One* **12**, e0173271 (2017).

30. Chadwick, K. et al. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. *Blood* **102**, 906–915 (2003).

31. Woods, N.-B. et al. Brief report: efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines. *Stem Cells* **29**, 1158–64 (2011).

32. Ng, E. S. et al. Differentiation of human embryonic stem cells to HOXA+ homogenic vasculature that resembles the aorta-gonads-mesonephros. *Nat. Biotechnol.* **34**, 1168–1179 (2016).

33. Ditadi, A. et al. Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages. *Nat. Cell Biol.* **17**, 580–91 (2015).

34. Wang, X. et al. Genome-wide analysis of PDX1 target genes in human pancreatic progenitors. *Mol. Metab.* **9**, 57–68 (2018).

35. Deasy, R. M. et al. A role for cell sex in stem cell-mediated skeletal muscle regeneration: Female cells have higher muscle regeneration efficiency. *J. Cell Biol.* **177**, 73–86 (2007).

36. Nakada, D. et al. Oestrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. *Nature* **505**, 555–558 (2014).

37. Li, Y. et al. Cell sex affects extracellular matrix protein expression and proliferation of smooth muscle progenitor cells derived from human pluripotent stem cells. *Stem Cell Res. Ther.* **8**, 156 (2017).

38. Pouthal, D. & Benvenisty, N. Sex-dependent gene expression in human pluripotent stem cells. *Cell Rep.* **8**, 923–932 (2014).

39. Venushi, G. I. et al. NOTCH signaling specifies arterial-type definitive hemogenic endothelium from human pluripotent stem cells. *Nat. Commun.*, https://doi.org/10.1038/s41467-018-04134-7 (2018).

40. Park, M. A. et al. Activation of the Arterial Program Drives Development of Definitive Hemogenic Endothelium with Lymphoid Potential Activation of the Arterial Program Drives Development of Definitive Hemogenic Endothelium with Lymphoid Potential. *Cell Rep.* **23**, 2467–2481 (2018).

41. Lian, X. et al. A Small Molecule Inhibitor of Src Family Kinases Promotes Simple Epithelial Differentiation of Human Pluripotent Stem Cells. *PLoS One* **8**, 1 (2013).

42. Randolph, L. N., Bao, X., Zhou, C. & Lian, X. An all-in-one, Tet-On 3G inducible PiggyBac system for human pluripotent stem cells and derivatives. *Sci. Rep.* **7**, 1549 (2017).

43. Bao, X. et al. Human pluripotent stem cell-derived epicardial progenitors can differentiate to endocardial-like endothelial cells. *Bioeng. Transl. Med.* **2**, 201–211 (2017).
Acknowledgements
We thank all the members in the Lian Lab for their support of this project. This work was supported by NIH Trailblazer Award R21EB026035 to X.L.L., Pennsylvania State University’s Biomedical Engineering Department, Biology Department, and Huck Institutes of the Life Sciences lab startup funding to X.L.L.

Author contributions
L.N.R. designed and performed experiments, analyzed data, and wrote the manuscript. X.B. designed and performed experiments. M.O. performed experiments. X.L.L. designed experiments, wrote the manuscript, and supervised the project.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-019-53054-z.

Correspondence and requests for materials should be addressed to X.L.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019